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Objective
To assess immediate clinical and echocardiographic results
of the use of cryopreserved aortic homografts for aortic valve
replacement.
Material
Eighteen patients with aortic valve disease underwent aortic
valve replacement, receiving a cryopreserved aortic homograft,
15 were male, 10 had aortic regurgitation, and 8 had aortic
stenosis. Age ranged from 18 to 65 years (mean, 44.5 ± 18.14
years). Four patients had infective endocarditis, 12 patients were
in functional class II, and 6 patients were in functional class III
(NYHA). Left ventricular function was normal in 15 patients.
Results
Hospital mortality was 5.5% (1 patient) due to respiratory
distress; the other patients were discharged from the hospital
between the fifth and eighth postoperative days in functional
class I. Maximal aortic transvalvular gradient, on echocardiogra-
phy, ranged from 0 to 30 mmHg, with a mean of 10.9 ± 9.2
mmHg. Five patients did not have any degree of regurgitation
through the aortic homograft, 11 patients (61.1%) had minimal
regurgitation, and 2 had mild regurgitation. Duration of extra-
corporeal circulation ranged from 130 to 220 minutes (mean,
183.9 ± 36.7 minutes). Duration of aortic clamping ranged from
102 to 168 minutes (mean, 139.14 ± 25.10 minutes). Bleeding
in the postoperative period ranged from 210 to 1220 mL, with a
mean of 511.4 ± 335.1 mL. Reoperations were not necessary.
Duration of orotracheal intubation ranged from 2 hours 50 minutes
to 17 hours with a mean of 9.14 ± 3.6 hours.
Conclusion
Cryopreserved aortic homografts may be routinely used with
low hospital morbidity and mortality.
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The idea of using an aortic homograft (grafts derived from
humans) for the treatment of aortic valve disease is not new and
is often mixed with the history of aortic valve replacement. Actually,
homografts were the first biological prostheses successfully used
in the orthostatic position by Ross 1 and Barrat-Boyes 2 in 1962.
These authors, working independently, used the subcoronary te-
chnique proposed by Duram and Gunning 3 and used “fresh” ho-
mografts, sterilized in antibiotic solutions and maintained in a
nutritional solution, enabling storage for up to a month.
The limitations on the use of homografts included the difficulties
in obtaining them, inefficient sterilization techniques, and the
greater risk of valve regurgitation due to distorted or unaligned
commissures, observed in the subcoronary technique, used in the
first series 4-10. On the other hand, the development of mechanical
prostheses and biological prostheses, which were easier to obtain
and maneuver, led to the replacement of the homograft.
Subsequently, the development of cryopreservation 11 enabling
storage for long periods (up to 10 years) and obtaining valves from
donors, with the heart still beating, and greater cell viability,
aroused interest in homografts again, because of their excellent
hemodynamic profile, low transvalvular gradients, and minimal
incidence of thromboembolism and endocarditis 6,12-14. Additionally,
they are considered the ideal replacement prostheses in patients
with active endocarditis 15.
The objective of this study was to present immediate results,
up to 30 days after replacement, with the use of cryopreserved
aortic homografts, in the aortic position, for the treatment of
aortic valve disease.
Methods
Eighteen patients with aortic valve disease and an indication for
replacement were selected to receive cryopreserved aortic homografts.
The use of cryopreserved aortic homografts was approved in
accordance with the guidelines of the Medical Ethics Committee.
Fifteen patients were male, 10 had aortic regurgitation, and
8 had aortic stenosis. Age ranged from 18 to 65, (mean,
44.5±18.14 years). Four patients had infective endocarditis, and
in 1 patient endocarditis was complicated by 2 valve ring absces-
ses. Twelve patients were in functional class II, and 6 patients
were in functional class III (NYHA).
Left ventricular function was normal in 15 patients, 2 had
mild dysfunction, and 1 had severe left ventricular dysfunction.
Exclusion criteria were: valvular reoperations, associated co-
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ronary disease, chronic renal disease, chronic obstructive pulmonary
disease, peripheral artery diseases with severe clinical involvement,
associated carotid lesions, associated multiple severe valvular
diseases.
Patients underwent a midline sternotomy. Extracorporeal cir-
culation was installed, with aortic and right atrial cannulation.
Surgery was performed with mild hypothermia at 28°C.
Myocardial protection was performed through continuous re-
trograde cardioplegia through the coronary sinus in 10 patients
and, in 8 patients, it was anterograde, through the coronary ostia,
intermittent, every 20 minutes. Cold blood cardioplegia was used
with potassium added (15mEq/L), only during induction, in the
dosages. Perfusate blood was used without adding any potassium
or other substances.
We used in all patients, tranexamic acid, albumin, corticoste-
roids, and we performed perfusate ultrafiltration, during the entire
period of extracorporeal circulation.
The replacement technique used was the aortic root replace-
ment with reimplantation of coronary arteries (root replacement).
We started with total aortic section, approximately 2cm above
the sinus tubular junction. We performed aortic valve leaflet re-
section, valvular annulus decalcification when necessary, and mea-
sured the aortic annulus.
With the measurement of the aortic annulus, the cryopreserved
aortic homograft was chosen, usually being 1- to 2-mm smaller
than the aortic annulus. Next, thawing was performed in the
operating room in 15 minutes (fast defrost).
While thawing was taking place, left and right coronary ostia
were isolated. Simple 3-0 polyester stitches were passed over
the aortic valvular annulus and in the valvular annulus of the aortic
homograft. The homograft was lowered until the annulus and all
the stitches were tied, leaving a Teflon tape fixed within each
tied stitch, aiming at reinforcing hemostasia, and avoiding future
dilations of the aortic annulus. Next, reimplantation of the coronary
arteries was performed, with continuous sutures, using a 6/0 po-
lypropylene. End-to-end anastomosis was performed of the distal
end of the homograft and of the patient’s aorta with a continuous
suture 4/0 polypropylene.
During the procedure, left chambers were decompressed
through a vacuum positioned in the left ventricle through the
right superior pulmonary vein or through the tip of the left ventricle.
This suction is also used to withdraw air and help in the restoration
of left ventricular function, after aortic declamping.
In the intraoperative period, duration of extracorporeal circu-
lation and myocardial anoxia (duration of aortic clamping) were
assessed, obtained right from the perfusion chart. The need for
performing associated procedures was also assessed.
In the postoperative period, the main clinical morbidities, such
as the presence of myocardial infarction, stroke, acute renal failure,
bleeding, need for reoperation, duration of orotracheal intubation,
and respiratory complications, were assessed. Additionally, all pa-
tients underwent transthoracic echocardiography before hospital
discharge, between the fifth and eighth postoperative days.
Results
Aortic homograft number 20 was used in 6 patients, number
22 in 10 patients, and number 24 in 2 patients.
Five patients underwent associated procedures, such as pos-
terior enlargement of aortic annulus (Managuan) in 2 patients
with congenital aortic stenosis, mitral valve plastia in 2 patients,
and replacement in 1 patient who had infective endocarditis with
ring abscess. Those abscesses were resected using bovine peri-
cardium, and later placement of the aortic homograft.
Duration of extracorporeal circulation ranged from 130 to 220
minutes (mean, 183.9 ± 36.7). Duration of aortic clamping ranged
from 102 (mean, 139.14 ± 25.10) minutes.
Hospital mortality was 5.5% (1 patient). This patient expe-
rienced bleeding in the aortic annulus at the end of the procedure,
and it was necessary to resort to extracorporeal circulation. Because
of that, total duration of extracorporeal circulation was prolonged,
and the patient developed, in the postoperative period, respiratory
failure from noncardiogenic pulmonary edema, leading to death
on the seventh postoperative day.
None of the patients had electrocardiographic alterations that
suggested ischemia or myocardial infarction due to coronary ostia
mobilization; likewise, neither of the patients had low cardiac
output syndrome.
Bleeding in the postoperative period ranged from 210 to
1220 mL (mean, 511.4 ± 335.1). No reoperations were
necessary because of bleeding or coagulopathy.
None of the patients experienced neurological complications.
The orotracheal intubation period ranged from 2 hours and
50 minutes to 17 hours (mean, 9.14 ± 3.6). No respiratory
complications occurred that required orotracheal reintubation.
All patients were discharged from the hospital between the
fifth and eighth postoperative days in functional class I (NHYA).
All patients underwent bidimensional echocardiography before
hospital discharge on the fifth postoperative day.
The maximal aortic transvalvular gradient ranged from zero to
30 mm Hg, with a mean of 10.9 ± 9.2 mmHg. In 2 patients,
the echocardiogram revealed a normal aortic valve.
Five patients did not have any level of regurgitation by the
homograft, 11 patients (61.1%) had minimal regurgitation, and
2 patients had mild regurgitation.
None of the patients experienced homograft dysfunction that
required reoperation to exchange the homograft.
Discussion
In this study, it was found that implantation of cryopreserved
aortic homografts by using the root replacement technique may
be performed with low morbidity and mortality. Additionally,
cryopreserved aortic homografts have excellent hemodynamic per-
formance with a low transvalvular gradient, minimal regurgitation,
and none of the patients experienced homograft dysfunction requiring
intervention in the immediate postoperative period.
The following 2 variables influenced the clinical outcome in
the development of the homografts: the preservation and the
replacement technique. For these reasons, heterogeneous results
are observed in the literature 4,5.
Efficiency of the preservation technique is assessed by the
ability to preserve cellular viability, and this is assessed by the
percentage of viable fibroblasts after valve implantation 16,17.
Homografts are classified according to the level of cell viability
into homovital, viable, and nonviable 17. The difference is in the
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level of cellular viability, which varies depending on the preservation
technique used.
“Homovital” (fresh) grafts are withdrawn from donors with the
heart still beating, preserved in nutrient solutions, and implanted
within 48 hours. Viable homografts are those that contain at least
50% of the live fibroblasts, achieved with cryopreservation 11. The
nonviable homografts are those that do not contain live cell elements,
lost during a warm ischemia period or during the sterilization and
the preservation process. This preservation takes place in media
nutrients at 4°C temperature 17,18.
It is important to point out that this kind of preservation allows
for a short period of storage, and this homograft must be used
within 4 to 6 weeks at the most, whereas cryopreservation allows
for long storage periods (up to 10 years).
Because of the cellular viability and the longer storage period
available, cryopreservation has become the most common method
currently used. In addition, several studies have demonstrated
more favorable clinical results, reduced valvular regurgitation index,
and need for reoperation, with cryopreserved homografts (viable)
when compared with homografts preserved in nutrient solution
(nonviable) 19-22.
Just as the valvular preservation methods influence the clinical
results, the replacement technique is another extremely important
factor in the immediate and late clinical outcomes.
Three types of replacement techniques are available for im-
plantation of the aortic valve homograft. The first technique used
was the subcoronary technique also known as free-hand, with 2
suture lines; the lower suture line is initiated in the lower part of
the aortic valve annulus continuously, and the other suture line is
subcoronary and by-passing the coronary ostia.
The second technique is the root replacement technique, more
elaborated, where all of the aortic root is replaced and requires
reimplantation of coronary arteries.
The third is the mini-root technique where the patient’s aorta
is maintained and covers the homograft, which is placed within
it. Coronary artery reimplantation is also necessary.
Although several studies have reported satisfactory results using
the subcoronary technique19,21, this technique has a greater risk
of aortic regurgitation. Recently, a high incidence of aortic valvular
regurgitation has been described, ranging from 46 to 80% 8,23,24.
Rotating and turning the valve upside down, using continuous
sutures, and especially dilating the sinus tubular junction, hindering
proper alignment of the commissures, are considered the main
reasons for valvular regurgitation in the postoperative period 25,26.
On the other hand, comparative analyses have demonstrated
more satisfactory clinical results with homografts using the root re-
placement technique, with a lower occurrence of valvular regur-
gitation, lower gradients, and a decreased need for reoperations 23,27.
In the present study, all homografts were cryopreserved, and
the root replacement technique was used in all patients. Only 1
patient had mild aortic regurgitation in the postoperative period in
the hospital, and the remaining patients had minimal or no aortic
failure. Additionally, transvalvular gradients were low (mean,
10.9 mmHg). Only 1 patient had an increased maximal gradient
(30 mmHg); 1 case was congenital stenosis, requiring enlargement
of the aortic annulus, which may not have been ideal.
The occurrence of these low gradients and the absence of
regurgitation confirm the excellent hemodynamic performance of
cryopreserved aortic homografts used with the root replacement
technique.
The absence of valvular support and the preservation of sinus
tubular junction integrity determine proper blood flow throughout
the aortic root, in the Valsalva sinus, and coronary ostia. Then,
there will be a lower incidence of valvular regurgitation and a
lower transvalvular gradient when compared with conventional
prostheses (mechanical or biological) placed with support 28,29.
These low transvalvular gradients will reflect in the complete
remission of ventricular hypertrophy 28, with improved left ventricu-
lar function 30, which may result in an increase in late survival 31.
Thus, it is possible to infer that the use of aortic homografts
leads to an improvement in the clinical condition of the patients, and
a ventricular reshaping with a possible impact on their late survival.
Another issue that has always been discussed is that surgery for
replacement with homografts is longer, because of the more difficult
operative technique, thus requiring a longer duration of extracorporeal
circulation and aortic clamping (myocardial anoxia). This fact is often
used to indicate that homograft surgery is a riskier procedure and
may cause complications in the postoperative period.
Although the duration of extracorporeal circulation and anoxia
is a real complicating factor, the literature has demonstrated that
a longer duration of extracorporeal circulation is well tolerated,
and it is not the main morbidity factor in the postoperative period.
A technical complication occurred in our material in the in-
traoperative period, leading to a prolonged duration of extracorporeal
circulation and mortality. In the 17 patients without operative
technique problems, the mean 183.9-minute duration of extra-
corporeal circulation was well tolerated, and no bleeding, low
cardiac output, myocardial infarction, or other morbidities occurred
related to extracorporeal circulation or to myocardial anoxia.
Hospital mortality with the use of homografts varies from 1.7
to 17% 27,32,33. This great variability is given to the heterogenous
population receiving the homografts. Because they are resistant
to the development of endocarditis, aortic homografts have been
used in patients with infective endocarditis, with annulus abscess,
in addition to diseases with aortic root dilations.
Dossche and cols.32, using the root replacement technique,
reported a hospital mortality of 9.1%, explaining that this mortality
was due to the complexity of the lesions associated with the
aortic valve treatment, such as aortic dilations, endocarditis, and
annulus abscess. They report only 1 death in the beginning of the
study from replacement technique failure.
Likewise, Prager and cols. 27 had a 17% mortality due to
morbidities associated with aortic dissection and extensive infec-
tions in the aortic root.
On the other hand, O´Brien and cols. 33 reported a 1.7%
mortality using the root replacement technique, and Yacoub and
cols.34, reporting similar mortality rates, did not observe differences
between the subcoronary technique free-hand, or the root repla-
cement technique.
In our study, 1 patient had complicated endocarditis and annulus
abscess; 2 patients underwent associated procedures, such as
posterior aortic annulus enlargement, and 1 patient had severe
ventricular preoperative dysfunction. Despite these morbidities,
our only death (5.5%) occurred in the third patient undergoing
replacement, without morbidities who had aortic bleeding at the
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aortic annulus, because of a technical failure that may be attributed
to the learning curve of the procedure. In the next 15 patients
undergoing replacement, no mortality or hospital morbidity occurred.
Therefore, for patients with isolated aortic valve disease, cryopre-
served homograft will not increase hospital morbidity and mortality,
and the possible complications are more commonly associated
with preoperative conditions, such as ventricular function, infective
endocarditis, and other related morbidities, rather than with the
replacement technique itself.
From the results obtained, considering the excellent hemody-
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namic performance of cryopreserved homografts, with low trans-
valvular gradients, and minimal regurgitation, we believe that cryo-
preserved aortic homografts may be routinely used in patients
with aortic valve disease and preserved left ventricular function.
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